156 related articles for article (PubMed ID: 15482785)
1. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics.
La Marca A; Orvieto R; Giulini S; Jasonni VM; Volpe A; De Leo V
Fertil Steril; 2004 Oct; 82(4):970-2. PubMed ID: 15482785
[TBL] [Abstract][Full Text] [Related]
2. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
[TBL] [Abstract][Full Text] [Related]
3. Müllerian inhibiting substance and disrupted folliculogenesis in polycystic ovary syndrome.
Wang JG; Nakhuda GS; Guarnaccia MM; Sauer MV; Lobo RA
Am J Obstet Gynecol; 2007 Jan; 196(1):77.e1-5. PubMed ID: 17240243
[TBL] [Abstract][Full Text] [Related]
4. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
5. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N
Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
[TBL] [Abstract][Full Text] [Related]
6. Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology.
Bayrak A; Terbell H; Urwitz-Lane R; Mor E; Stanczyk FZ; Paulson RJ
Fertil Steril; 2007 Apr; 87(4):870-5. PubMed ID: 17224152
[TBL] [Abstract][Full Text] [Related]
7. Relationship between serum müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women.
Cook CL; Siow Y; Brenner AG; Fallat ME
Fertil Steril; 2002 Jan; 77(1):141-6. PubMed ID: 11779604
[TBL] [Abstract][Full Text] [Related]
8. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
Barber TM; Wass JA; McCarthy MI; Franks S
Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
[TBL] [Abstract][Full Text] [Related]
9. Serum Müllerian-inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome.
Siow Y; Kives S; Hertweck P; Perlman S; Fallat ME
Fertil Steril; 2005 Oct; 84(4):938-44. PubMed ID: 16213847
[TBL] [Abstract][Full Text] [Related]
10. Müllerian-inhibiting substance reflects ovarian findings in women with polycystic ovary syndrome better than does inhibin B.
Chu MC; Carmina E; Wang J; Lobo RA
Fertil Steril; 2005 Dec; 84(6):1685-8. PubMed ID: 16359965
[TBL] [Abstract][Full Text] [Related]
11. Serum leptin levels correlate with clinical and biochemical indices of insulin resistance in women with polycystic ovary syndrome.
Pehlivanov B; Mitkov M
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):153-9. PubMed ID: 19340711
[TBL] [Abstract][Full Text] [Related]
12. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
Shi Y; Guo M; Yan J; Sun W; Zhang X; Geng L; Xu L; Chen Z
Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
[TBL] [Abstract][Full Text] [Related]
13. Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment.
Fleming R; Harborne L; MacLaughlin DT; Ling D; Norman J; Sattar N; Seifer DB
Fertil Steril; 2005 Jan; 83(1):130-6. PubMed ID: 15652898
[TBL] [Abstract][Full Text] [Related]
14. Increased anti-Müllerian hormone serum concentrations in prepubertal daughters of women with polycystic ovary syndrome.
Sir-Petermann T; Codner E; Maliqueo M; Echiburú B; Hitschfeld C; Crisosto N; Pérez-Bravo F; Recabarren SE; Cassorla F
J Clin Endocrinol Metab; 2006 Aug; 91(8):3105-9. PubMed ID: 16720659
[TBL] [Abstract][Full Text] [Related]
15. Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance.
Sepilian V; Nagamani M
J Soc Gynecol Investig; 2005 Feb; 12(2):129-34. PubMed ID: 15695109
[TBL] [Abstract][Full Text] [Related]
16. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome.
Yilmaz M; Ergün MA; Karakoç A; Yurtçu E; Cakir N; Arslan M
Gynecol Endocrinol; 2006 Jun; 22(6):336-42. PubMed ID: 16785159
[TBL] [Abstract][Full Text] [Related]
17. The androgenic profile of women with non-insulin-dependent diabetes mellitus.
Tok EC; Ertunc D; Evruke C; Dilek S
J Reprod Med; 2004 Sep; 49(9):746-52. PubMed ID: 15493567
[TBL] [Abstract][Full Text] [Related]
18. [Interrelationship of abnormal family history in the first degree relatives and clinical phenotype of patients with polycystic ovary syndrome].
Wang Y; Mao WW; Chen YJ; Li MZ; Qiao J; Wang LN
Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):756-60. PubMed ID: 18307903
[TBL] [Abstract][Full Text] [Related]
19. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome.
Ardawi MS; Rouzi AA
Fertil Steril; 2005 Jun; 83(6):1708-16. PubMed ID: 15950640
[TBL] [Abstract][Full Text] [Related]
20. Body fat composition and distribution in women with polycystic ovary syndrome.
Cosar E; Uçok K; Akgün L; Köken G; Sahin FK; Arioz DT; Baş O
Gynecol Endocrinol; 2008 Aug; 24(8):428-32. PubMed ID: 18850379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
